<SEC-DOCUMENT>0001104659-21-072082.txt : 20210526
<SEC-HEADER>0001104659-21-072082.hdr.sgml : 20210526
<ACCEPTANCE-DATETIME>20210526070509
ACCESSION NUMBER:		0001104659-21-072082
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210525
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210526
DATE AS OF CHANGE:		20210526

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		21962719

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2117516d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event reported):
May 25, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-12584</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-3808303</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9605 Medical Center Drive, Suite 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (301) 417-4364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; border: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 20%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 42%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE American</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Item
8.01. Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 26, 2021, Synthetic Biologics, Inc. (the
 &ldquo;Company&rdquo;) issued a press release announcing that it had received on May 25, 2021 notification from the NYSE American LLC
(the &ldquo;Exchange&rdquo;) that the Company has regained compliance with all of the NYSE American LLC continued listing standards set
forth in Part 10, Section 1003 of the NYSE American Company Guide (the &ldquo;Company Guide&rdquo;). The Company previously received notification
from the NYSE American citing failure to comply with the minimum stockholders&rsquo; equity continued listing standard as set forth in
Part 10, Section 1003 of Company Guide. As a result of management&rsquo;s efforts to regain compliance, the Exchange has informed the
Company that it has cured the previously cited deficiencies and is in full compliance with the continued listing standards set forth in
Part 10, Sections 1003 (i), (ii), and (iii) of the Company Guide. The Company reported stockholders&rsquo; equity of approximately $79.6 million
in its most recent Form 10-Q, filed with the Securities and Exchange Commission on May 5, 2021. Effective at the start of trading on May
26, 2021, the &ldquo;.BC&rdquo; designation, signifying non-compliance with NYSE American listing standards, will be removed from the
 &ldquo;SYN&rdquo; trading symbol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The press release attached as Exhibit 99.1 to
this Current Report on Form 8-K, which is incorporated herein by reference, includes &ldquo;safe harbor&rdquo; language pursuant to the
Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the slide presentation are
 &ldquo;forward-looking&rdquo; rather than historical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company undertakes no duty or obligation to
update or revise information included in this Current Report on Form 8-K or the press release attached as Exhibit 99.1 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Item
9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">(d)
Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid">Exhibit<BR>
                                    No.</P></TD>
    <TD STYLE="font-size: 10pt; width: 4%">&nbsp;&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid">Description</P></TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><A HREF="tm2117516d1_ex99-1.htm">99.1</A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="tm2117516d1_ex99-1.htm">Press release issued by Synthetic Biologics, Inc.
    dated May 26, 2021</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: May 26, 2021</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title: Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">and Chief Financial Officer</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 15%; border-bottom: black 1pt solid; text-align: center"><B>Exhibit</B><BR>
    <B>Number</B></TD>
    <TD STYLE="vertical-align: top; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 80%; border-bottom: black 1pt solid"><B>Description</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="tm2117516d1_ex99-1.htm">99.1</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2117516d1_ex99-1.htm">Press release issued by Synthetic Biologics, Inc. dated May 26, 2021</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2117516d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2117516d1_ex99-1img01.jpg" ALT=""></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Synthetic Biologics Regains Compliance with
NYSE American Continued Listing Standards</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rockville, MD, May 26, 2021 &ndash;</B> Synthetic
Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed
to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today receipt, on May 25, 2021, of notification
from the NYSE American LLC (the &ldquo;Exchange&rdquo;) that the Company has regained compliance with all of the continued listing standards
set forth in Part 10, Section 1003 of the NYSE American Company Guide (the &ldquo;Company Guide&rdquo;) relating to the Exchange&rsquo;s
continued listing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company previously received notification from
the NYSE American citing failure to comply with the minimum stockholders&rsquo; equity continued listing standard as set forth in Part
10, Section 1003 of the Company Guide. As a result of management&rsquo;s efforts to regain compliance, the Exchange has informed the Company
that it has cured the previously cited deficiencies and is in full compliance with the continued listing standards set forth in Part 10,
Sections 1003 (i), (ii), and (iii) of the Company Guide. The Company reported stockholders&rsquo; equity of approximately $79.6 million in
its most recent Form 10-Q, filed with the Securities and Exchange Commission (SEC) on May 5, 2021. Effective at the start of trading on
May 26, 2021, the &ldquo;.BC&rdquo; designation, signifying non-compliance with NYSE American listing standards, will be removed from
the &ldquo;SYN&rdquo; trading symbol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American: SYN)
is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal
(GI) diseases in areas of high unmet need. The Company&rsquo;s lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade
certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage,
(b) <I>Clostridioides difficile</I> infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance
(AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020,
a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat
both local GI and systemic diseases. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified
by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot; &quot;anticipates,&quot;
 &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions, and includes statements
regarding continuing to comply with the continued listing requirements of the NYSE American and the potential benefits of SYN-004 and
SYN-020. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release
and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ
materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors
that could cause actual results to differ materially from current expectations include, among others,&nbsp; the ability of Synthetic Biologics'
product candidates to demonstrate safety and effectiveness, as well as results that are consistent with prior results, Synthetic Biologics'
clinical trials continuing enrollment as expected, a failure to receive the necessary regulatory approvals for commercialization of Synthetic
Biologics' therapeutics, including approval of proposed trial designs, a failure of Synthetic Biologics' clinical trials, and those conducted
by investigators, for SYN-004, SYN-020 to be commenced or completed on time or to achieve desired results and benefits, a failure to file
INDs when anticipated, a failure of Synthetic Biologics' clinical trials to continue enrollment as expected or receive anticipated funding,
a failure of Synthetic Biologics to successfully develop, market or sell its products, Synthetic Biologics' inability to maintain its
material licensing agreements, or a failure by Synthetic Biologics or its strategic partners to successfully commercialize products, Synthetic
Biologics' ability to achieve acceptance of its product candidates in the marketplace and the successful development, marketing or sale
of Synthetic Biologics' products by competitors that render Synthetic Biologics' products obsolete or non-competitive, Synthetic Biologics'
ability to continue to comply with the continued listing requirements of the NYSE American, the continued maintenance and growth of Synthetic
Biologics' patent estate, Synthetic Biologics becoming and remaining profitable, Synthetic Biologics' ability to obtain or maintain the
capital or grants necessary to fund its research and development activities, a loss of any of Synthetic Biologics' key scientists or management
personnel and other factors described in Synthetic Biologics' Form 10-K for the year ended December 31, 2020 and its other filings with
the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date
of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on
account of new information, future events, or otherwise, except as required by law. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Synthetic Biologics, Inc. (Corporate and Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director, Corporate Communication, (240) 660-2000,
info@syntheticbiologics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ogilvy (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory Kelley, Senior Vice President, (404) 836-2302, gregory.kelley@ogilvy.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2117516d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2117516d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !1 1T# 2(  A$! Q$!_\0
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MND*2KVZ@CU!]*]BJAJ&G:?J3;+R&*61!_P "4?4<BOL,5PS1=-+#NTO-Z/\
MR^1\]0S>:F_:JZ\NAY)OHWUUFN>"Y(D:;27:51R87/S?@>_T-<6Q9&97!5E.
M"",$&OEL7E];"2Y:T;?D_1GN8>O2Q$>:F[G=>!-:(D&FW#94Y,!/8]U_J*[B
MO#X;AX)HY8B5DC8,I]"*]HTZZ6]L+>Y3[LJ!_ID5]=PYC95:3H3>L-O3_@?D
M>%F^%5*:JQVE^?\ P2Q1117TAXX4444 >!?'3X9ZS?\ B'_A*?"\;W,Q5#/;
MQ'$J.G"NGKP!QUR.]9?A[X^:QI4BV/B_1S/+'\KR1@P3?5D88)^F*WO$OQ2U
M70?C1_8MY=VL/AR.6))B\0W(K1@Y+]?O'->B>+'\%:YH,TFOW.D7-AY9;SFE
M0E1ZHP.0?3'-:WT2DC.VK<69OA1/ _C6TU/5/#UM;+=WL4D%Y*D0CN4\P8;=
MGH3USR#CO7S-XP\(6?A3XB-H6I--_9*S1_OUQYAMWQ\V<8R!GMU%=7^S:]PG
MQ09+$R&S>UF$WO&"-A;WSC\S7;_M3^'/M&E:;XAA3+VS?9+@C_GF_*G\&R/^
M!52]V5B7[T;G)_M(:!H^C7V@-9S3R7K6:P%9&4J((5"HW ZDGKTX-=O\+_A1
M8R?#*YBU2:[BG\0V\4EPL94>4JMOC"Y'7!&<Y_"O'M(-]\2_'WAZPOMS!88;
M60@YQ#$N7;ZG!_$U]E@1P1 #;'&@P.P4"E-N*41Q2;;/C#PMX?N3\5&\/Z+J
M+V,WVFXLEO0OSK& P8C'\14$<8ZUK_%WX8I\/H],O;'4IKJ.YD9"SJ$DCD W
M @C\?<8JQX$EC'[0_F&1!&=2NR'W#:<B3'-=_P#M6R(?#^A('7>+MCMSSC8>
M<5;D^9(5ERMF1XRT0^-O@UI'C/5+V8:CIFG."H52)V#[26)YR=N>/6N<^ W@
M&T\67LNK7-[/;R:1>021QQHI$F#OY)Y'W>U=SISK)^RM.D;*SI8R;E4Y*_OB
M>?3BL[]EC4K&TM?$-O=WEO!-)-"R)+(%+C##C/7GBINU%V'9-H=^UET\,_6X
M_DE9>E_!N?Q-X"LM=N]?FDOFL0]K;M&&BC0+E(\GD<=QCD]ZTOVL)$9O#:*Z
MEU,^Y01D<)U%>G_#2>$?"71&,L85-.4,Q884[>A/:ES.,%8=DY.YY'^RWXAN
M8M6U/0YYF^PFV^UQ1L<B)U8!L>@(89^E<K=7EW\7?B6T&HZFMCI>Z0Q>:PV6
M\"]-H) +MQSZGT%6OV<0DGC^\B>18_-TV>-2QQDEDZ5R?A#0](E\:_V)XSN)
M].ME>2W>56">7,IP-Q8$ '!&?<5=ES-D7T2-WQAH\GPH\5Z;>^%M=%XKH94D
M1ESE2 T<@4X*D$?F?2M;XZ^&[.%=/\8VMS,\GB)EF:!U7;$#$I&".3^-=5J/
MPE^&VF11M>>*;B%965$'VN$EBQP, +D]:7]I;3H]*\%^$K"W+O!:2FW1GY)"
MQ8&?? I*5VAN-DS1_9[\ 6EGIVG^,%O9VN;ZUDB:W*J$4%\<'K_!^M>0?&KP
M98>"O$ZV&G2S3P3VWVG,^TLI+,,9 &1Q7T1\!=2L9?AGH-G'>6[7<<<BO )!
MO4B1B<KUZ$?G7CG[4DB2>/+7RW5]NG*IVD'!WOP?>E%OG')+D.O_ &@?&E[H
MWA[1= TN=[:2]M1-<RQG#>4  %!'3)SGV&.]<]9_ :2X\"?VQ)J,G]KO:FZ2
MS6$%"=NX(3U+$<9]35;]I.QD:[\-:G%B2TGTX6PD4Y7>IW8R/9OT->V:1X_T
M"+X>6VMOJ%MY<-FI>$2J)/,"\Q[>N[(QBE=QBN4+)MW.)_9B.MP:?K=EK$6H
M0VL30M;1W<;J$W!]P3<.G X%>V3/Y<+O_=4M^5<1\,/B+;^/_P"T#9Z9=6:6
M>P,\S*0Q;/ QW&/UKM;M#):S(.K(P_2LJC>KZFM-+1'AL5VZ727(.9%D$OXY
MS7K^M6ZZYX:E6W(8S1"2(^_4?X5XF&(&#U'%>B?#77T:/^R+I\.N6MR>XZE?
MJ.HKXC)*T5.>&J[5%;Y_\&_WGUV;8>7)&O3W@_P_X'Y'"%B"0<@C@@]J3?7=
M>.O"LK32:EI<9?=\T\*CG/\ >4=_<5Y[OKS<9@:F$J.G->C[H[\+B*>*IJ</
MFNQT=KXKUBUMA!%=DH!@%U#,!]366U]<-=&Y-Q+]H)R9=Q#9^M,M].O[F S6
M]E<RPC^-(R150L02#P1P0:FI.O*,?:2=EM>_X%0HT4WR)7ZVM^)Z+X4\:,\J
M6>L,#N(5+CISZ-_C5[QWX>6[MGU&S3%U$,R*H_UBC^HKRO?7K7P\U=M3T8P3
MMNGM2(R3U9?X3_3\*]W+L3]?@\%BM;K1]=/U73YIGCX_"O!26+P^G==/Z_X<
M\MW^]>K_  \G,WAB$$Y\MW3]<_UKSCQ=8C2_$%W;H,1$^9&/16YQ^!R/PKT'
MX9H5\,*Q_CF=A^>/Z5ED=*5''2IOHFG\FB\WE&I@XU%U::^=SJZ***^R/E0H
MHHH X[QU\./#WC3;+JMLT=ZJ[5N[=MDH'H3T8>Q!KSD?LX:2)MW]OWWEYZ>1
M'N_/_P"M7N]%4IR6S)<4]SF/ O@?1/!5E)!HMNPDEP9KB5MTLF.F3Z>PP*P/
MC7XD\/V/@G6]+U2Z@EO9[<QQ62R#S2[?<..H .&S[5Z-7FGC#X.Z'XK\3S:W
MJ5[J2S3!!)%%(H7"J  /ER.!1%J]Y UI9'"_LK^'#G5/$=PG_3E;L1UZ-(1^
M.T?@:]M\7Z#!XG\-WVC74TL,%V@1Y(L;E&0>,_2K>B:59:'I5MINEVZ6]G;K
MLCC7L/ZD]2>]9'Q&O+G3_!NH7-C,\%P@39(AP1\X%16J\J=1]-37#T'5G&BM
MY-+[SS8_L[>'R,?VQJH'_;/_ .)K<\9?!G2/%6N'5+S4M0AF,,<.V(IMP@P#
MR#5_X=ZO=WNO7UK%JLNJZ9%;H_G3J%=)2>5' )'7M6G\4;RYLO#MO+9W$MO(
M;V%"T3E25+<C([5BL9>DZW:YURRUQQ,<*VKNW?JKZK?Y&3X&^$VC>$_[56*Y
MNKZ#4K?[-/%<[=I3G/0#KFN6'[/6CQ:K%=6VMZA'!%*LL<11&9<$$#?^'I7M
MDS^7$[@9VJ3BO)].U;6X['1/$,VKSS"_U 6\MDRJ(E0L5^7T(Q55L4Z+5[N_
MY:+]2,+@'B8MII6T5[ZMINWX/</$WP.T7Q!XAU#5[G5-2CGO)3*Z(4VJ?097
M.*GM/@OH]MX1U'P^FIZB;6]N8[EY"4W*R= .,8/>O1/$$LD&@ZE-"Y26.VE=
M&'52%)!JCX%NI[WPAI-S=RM-<2P*SR-U8^IK3VSYU3\K_C8P6'_=.MTO;[U<
M\TM?V?-!M[J"==7U4M#(LB@F/JIS_=]JZ3XA?"70/&=X;^5IK#4F #W%OC]X
M!TWJ1@GWX-:_CZ]O8I=$T[3[M[-M1NQ#)/& 75<9XSWIO@.[OC?Z]I=_>27H
MT^X5(IY0-Y5ES@XZUG]:_>^SU]?E?\C=8!_5_;W7>VM[7Y;]M^FYP6C?L\>'
MK2Z674M2OKZ-3GR@%A5OJ5YQ]"*]*\9^$-+\6^'3H^II((%*M%)&V'B91@,"
M<]LCGKFLWQK>7LOB'1M'M=1DTVWN4FFGN(L!@$7.,GH*U/!$MZ^D.FHW]MJ$
MD4S(ES!('WI_#NQP&YH6)<ZCAVZ_=\^HI8+V=!5FUKTUO:[7:W1Z7N<5\/O@
MU8^#?$\6M0:O=74T<;QK&\2*"&&.2.:S+C]GO09[F:=M7U4-+(TC8,?4G/\
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< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
